HUTCHMED welcomes the approval of Surufatinib for the treatment of non-pancreatic neuroendocrine tumours. A 420-strong commercial team will now bring the drug – discovered and developed completely in-house – to doctors and patients across Mainland China to help fight cancer. It will be marketed under the brand name Sulanda®. The pharmaceutical innovator has also initiated a rolling submission of its New Drug Application to the US Food and Drug Administration.
